Structure-based development of new cyclic compounds targeting PSD-95 PDZ3 domain is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2023). On theSindex it has a DataRank of 0.104. It has been cited 1 time.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 5R01NS094440-04
A Novel Cyclic Peptide-Based Treatment for TBI
National Institutes of Health
Grant: 1R41MH118747-01A1
Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression
National Institutes of Health
Grant: 1R21MH104252-01A1
A novel BDNF potentiator for Treating Cognitive Dysfunction in Angelman Syndrome
NINDS NIH HHS
Grant: R01 NS094440
NIMH NIH HHS
Grant: R21 MH104252
NIMH NIH HHS
Grant: R41 MH118747
Fields of Study
Keywords